Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Filipits

Showing results (11-20 of 122) with videos related to

Pageof 13
Sort By:
Anticancer Research|April 12, 2003
Low p27Kip1 expression is an independent prognostic factor in gallbladder carcinomaMartin Filipits, Harald Puhalla, Friedrich Wrba
Clinical Lung Cancer|May 8, 2009
Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancerRobert Pirker, Wilma Minar, Martin Filipits
Breast Care (Basel, Switzerland)|June 20, 2014
Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial?Michael Knauer, Martin Filipits, Peter Dubsky
Targeted Oncology|December 3, 2020
The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with OsimertinibAnna Buder, Maximilian J Hochmair, Martin Filipits
Oncology|August 22, 2012
Taxanes for ovarian cancer during pregnancy: a systematic reviewFlora Zagouri, Theodoros N Sergentanis, Dimosthenis Chrysikos, et al.
Translational Lung Cancer Research|May 19, 2020
<i>EGFR</i> mutation tracking predicts survival in advanced <i>EGFR</i>-mutated non-small cell lung cancer patients treated with osimertinibAnna Buder, Maximilian J Hochmair, Ulrike Setinek, et al.
Gynecologic Oncology|September 13, 2012
mTOR inhibitors in breast cancer: a systematic reviewFlora Zagouri, Theodoros N Sergentanis, Dimosthenis Chrysikos, et al.
Gynecologic Oncology|April 17, 2012
Molecularly targeted therapies in cervical cancer. A systematic reviewFlora Zagouri, Theodoros N Sergentanis, Dimosthenis Chrysikos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2009
EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastasesKatharina Schmid, Natalie Oehl, Fritz Wrba, et al.
Nature Communications|February 5, 2015
PYK2 sustains endosomal-derived receptor signalling and enhances epithelial-to-mesenchymal transitionNandini Verma, Omer Keinan, Michael Selitrennik, et al.
Pageof 13

Showing results (11-20 of 122) with videos related to

Sort By:
Pageof 13
Anticancer Research|April 12, 2003
Low p27Kip1 expression is an independent prognostic factor in gallbladder carcinomaMartin Filipits, Harald Puhalla, Friedrich Wrba
Clinical Lung Cancer|May 8, 2009
Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancerRobert Pirker, Wilma Minar, Martin Filipits
Breast Care (Basel, Switzerland)|June 20, 2014
Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial?Michael Knauer, Martin Filipits, Peter Dubsky
Targeted Oncology|December 3, 2020
The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with OsimertinibAnna Buder, Maximilian J Hochmair, Martin Filipits
Oncology|August 22, 2012
Taxanes for ovarian cancer during pregnancy: a systematic reviewFlora Zagouri, Theodoros N Sergentanis, Dimosthenis Chrysikos, et al.
Translational Lung Cancer Research|May 19, 2020
<i>EGFR</i> mutation tracking predicts survival in advanced <i>EGFR</i>-mutated non-small cell lung cancer patients treated with osimertinibAnna Buder, Maximilian J Hochmair, Ulrike Setinek, et al.
Gynecologic Oncology|September 13, 2012
mTOR inhibitors in breast cancer: a systematic reviewFlora Zagouri, Theodoros N Sergentanis, Dimosthenis Chrysikos, et al.
Gynecologic Oncology|April 17, 2012
Molecularly targeted therapies in cervical cancer. A systematic reviewFlora Zagouri, Theodoros N Sergentanis, Dimosthenis Chrysikos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2009
EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastasesKatharina Schmid, Natalie Oehl, Fritz Wrba, et al.
Nature Communications|February 5, 2015
PYK2 sustains endosomal-derived receptor signalling and enhances epithelial-to-mesenchymal transitionNandini Verma, Omer Keinan, Michael Selitrennik, et al.
Pageof 13